ZFP36L3 Activators
Chemical activators of ZFP36L3 operate through a variety of molecular mechanisms to maintain the protein in an active state. Bisindolylmaleimide I, Go 6983, Ro-31-8220, and GF 109203X are all inhibitors of protein kinase C (PKC), a kinase that can phosphorylate and potentially inactivate ZFP36L3. By inhibiting PKC, these chemicals prevent phosphorylation of ZFP36L3, thus sustaining its activity. Similarly, LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinases (PI3K), which, when blocked, can curtail the phosphorylation cascade that may include ZFP36L3 as a substrate. As a result, the inhibition of PI3K by these compounds can also result in the maintenance of ZFP36L3 in its active form.
In parallel, SB203580 targets the p38 MAPK pathway, a different kinase pathway implicated in protein phosphorylation. By selectively inhibiting p38 MAPK, SB203580 can reduce the phosphorylation of its substrates, which may include ZFP36L3, leading to the preservation of ZFP36L3's active state. SP600125 works on the c-Jun N-terminal kinase (JNK) pathway, by blocking JNK, this inhibitor can prevent the phosphorylation of ZFP36L3, thereby contributing to its activation. Additionally, PD98059 and U0126, both inhibitors of MEK, work upstream of extracellular signal-regulated kinase (ERK). These inhibitors halt the MEK/ERK signaling pathway, which could otherwise phosphorylate and deactivate ZFP36L3. Lastly, Rapamycin acts on the mammalian target of rapamycin (mTOR) pathway, a central node in cell signaling that can affect the phosphorylation status of many proteins, including ZFP36L3. By inhibiting mTOR, Rapamycin can ensure that ZFP36L3 remains in a state conducive to its activity. Collectively, these chemicals use distinct but converging pathways to mitigate phosphorylation, thereby facilitating the sustained activity of ZFP36L3.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). ZFP36L3 is a protein that can be phosphorylated by PKC, and inhibition of PKC can lead to an increase in the functional activity of ZFP36L3 by preventing its inactivation through phosphorylation. Thus, Bisindolylmaleimide I can indirectly lead to the activation of ZFP36L3 by maintaining its dephosphorylated, active form. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of the phosphoinositide 3-kinases (PI3K). PI3K inhibition can block downstream AKT signaling, which is known to phosphorylate a range of targets, potentially including regulatory proteins like ZFP36L3. By preventing AKT-mediated phosphorylation, LY294002 can indirectly contribute to the activation of ZFP36L3 by preserving its active state that may be regulated by AKT-related pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway can phosphorylate various substrates that can include proteins like ZFP36L3. By inhibiting p38 MAPK, SB203580 may prevent the phosphorylation and subsequent inactivation of ZFP36L3, leading to its activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in the phosphorylation of many transcriptional regulators. By inhibiting JNK, SP600125 could prevent phosphorylation-mediated inactivation of ZFP36L3, resulting in its activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). ERK can phosphorylate a wide range of target proteins. Inhibition of MEK/ERK signaling by PD98059 can lead to the activation of ZFP36L3 by reducing the phosphorylation that may inactivate ZFP36L3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR is a central regulator of cell growth and proliferation and can influence the phosphorylation state of many proteins. By inhibiting mTOR, Rapamycin could indirectly activate ZFP36L3 by preventing its phosphorylation and potential inactivation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which, like PD98059, can prevent the activation of ERK. By doing so, U0126 can indirectly activate ZFP36L3 by reducing the phosphorylation that may inactivate it, thus preserving its active state. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go 6983 is a pan-PKC inhibitor, similar to Bisindolylmaleimide I. By inhibiting PKC, Go 6983 can indirectly activate ZFP36L3 by preventing the phosphorylation that might result in its inactivation, thus keeping ZFP36L3 in an active form. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is another PKC inhibitor that can prevent the phosphorylation of substrates by PKC. This inhibition can lead to the activation of ZFP36L3 by maintaining it in a dephosphorylated and active state. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor. By inhibiting AKT, it can prevent the phosphorylation of downstream proteins. This can lead to the activation of ZFP36L3 if it is indeed regulated by AKT phosphorylation, by preserving ZFP36L3's active form. | ||||||